×
Prelude Therapeutics Net Profit Margin 2020-2025 | PRLD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Prelude Therapeutics net profit margin from 2020 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
View More
Prelude Therapeutics Net Profit Margin 2020-2025 | PRLD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Prelude Therapeutics net profit margin from 2020 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$81.3B
Zoetis (ZTS)
$67.7B
Daiichi Sankyo, - (DSNKY)
$46.4B
Takeda Pharmaceutical (TAK)
$46.1B
BeOne Medicines - (ONC)
$31.9B
Sandoz Group AG (SDZNY)
$26.1B
Summit Therapeutics (SMMT)
$21.3B
Merck (MKKGY)
$17.2B
Shionogi (SGIOY)
$14.6B
United Therapeutics (UTHR)
$13.7B
Neurocrine Biosciences (NBIX)
$13.1B
Orion OYJ (ORINY)
$11.7B
IPSEN (IPSEY)
$10.9B
Stevanato Group S.p.A (STVN)
$8B
Corcept Therapeutics (CORT)
$7.2B
Grifols, S.A (GRFS)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.7B
Madrigal Pharmaceuticals (MDGL)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.4B
Hypermarcas (HYPMY)
$2.9B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.1B
Ocular Therapeutix (OCUL)
$1.9B
Endo (NDOI)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.8B